These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 35259259)

  • 61. Preclinical Drug Metabolism, Pharmacokinetic, and Pharmacodynamic Profiles of Ivosidenib, an Inhibitor of Mutant Isocitrate Dehydrogenase 1 for Treatment of Isocitrate Dehydrogenase 1-Mutant Malignancies.
    Chen Y; Nagaraja NV; Fan B; Utley L; Lemieux RM; Popovici-Muller J; Dang L; Kim H; Yan L; Su SM; Biller SA; Yang H
    Drug Metab Dispos; 2021 Oct; 49(10):870-881. PubMed ID: 34321251
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis.
    Norsworthy KJ; Mulkey F; Scott EC; Ward AF; Przepiorka D; Charlab R; Dorff SE; Deisseroth A; Kazandjian D; Sridhara R; Beaver JA; Farrell AT; de Claro RA; Pazdur R
    Clin Cancer Res; 2020 Aug; 26(16):4280-4288. PubMed ID: 32393603
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
    Bekaii-Saab TS; Bridgewater J; Normanno N
    Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
    [TBL] [Abstract][Full Text] [Related]  

  • 64. U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.
    Larkins E; Scepura B; Blumenthal GM; Bloomquist E; Tang S; Biable M; Kluetz P; Keegan P; Pazdur R
    Oncologist; 2015 Nov; 20(11):1320-5. PubMed ID: 26446239
    [TBL] [Abstract][Full Text] [Related]  

  • 65. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
    Blumenthal GM; Scher NS; Cortazar P; Chattopadhyay S; Tang S; Song P; Liu Q; Ringgold K; Pilaro AM; Tilley A; King KE; Graham L; Rellahan BL; Weinberg WC; Chi B; Thomas C; Hughes P; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2013 Sep; 19(18):4911-6. PubMed ID: 23801166
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study.
    Luo X; Jia W; Huang Z; Li X; Xing B; Jiang X; Li J; Si A; Yang T; Gao C; Lau WY; Shen F
    Oncotarget; 2017 Mar; 8(10):17246-17257. PubMed ID: 27783997
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
    Fathi AT; Kim HT; Soiffer RJ; Levis MJ; Li S; Kim AS; DeFilipp Z; El-Jawahri A; McAfee SL; Brunner AM; Amrein PC; Mims AS; Knight LW; Kelley D; Bottoms AS; Perry LH; Wahl JL; Brock J; Breton E; Marchione DM; Ho VT; Chen YB
    Clin Cancer Res; 2023 Jun; 29(11):2034-2042. PubMed ID: 37014667
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma to the BET inhibitor JQ1.
    Fujiwara H; Tateishi K; Kato H; Nakatsuka T; Yamamoto K; Tanaka Y; Ijichi H; Takahara N; Mizuno S; Kogure H; Matsubara S; Nakai Y; Koike K
    Cancer Sci; 2018 Nov; 109(11):3602-3610. PubMed ID: 30156013
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.
    Goyal L; Govindan A; Sheth RA; Nardi V; Blaszkowsky LS; Faris JE; Clark JW; Ryan DP; Kwak EL; Allen JN; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Chong DQ; Deshpande V; Borger DR; Iafrate AJ; Bardeesy N; Zheng H; Zhu AX
    Oncologist; 2015 Sep; 20(9):1019-27. PubMed ID: 26245674
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Not Available].
    Valéry M; Cervantes B; Smolenschi C; Boige V; Ducreux M; Cohen R; Hollebecque A
    Bull Cancer; 2022 Nov; 109(11S):11S21-11S27. PubMed ID: 36535759
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
    DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P
    J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel: U.S. Food and Drug Administration drug approval summary.
    Ning YM; Pierce W; Maher VE; Karuri S; Tang SH; Chiu HJ; Palmby T; Zirkelbach JF; Marathe D; Mehrotra N; Liu Q; Ghosh D; Cottrell CL; Leighton J; Sridhara R; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2013 Nov; 19(22):6067-73. PubMed ID: 24141628
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
    Cohen MH; Johnson JR; Chattopadhyay S; Tang S; Justice R; Sridhara R; Pazdur R
    Oncologist; 2010; 15(12):1344-51. PubMed ID: 21148614
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: REACHIN, a randomized, double-blind, phase II trial.
    Demols A; Borbath I; Van den Eynde M; Houbiers G; Peeters M; Marechal R; Delaunoit T; Goemine JC; Laurent S; Holbrechts S; Paesmans M; Van Laethem JL
    Ann Oncol; 2020 Sep; 31(9):1169-1177. PubMed ID: 32464280
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Circulating oncometabolite 2-hydroxyglutarate is a potential surrogate biomarker in patients with isocitrate dehydrogenase-mutant intrahepatic cholangiocarcinoma.
    Borger DR; Goyal L; Yau T; Poon RT; Ancukiewicz M; Deshpande V; Christiani DC; Liebman HM; Yang H; Kim H; Yen K; Faris JE; Iafrate AJ; Kwak EL; Clark JW; Allen JN; Blaszkowsky LS; Murphy JE; Saha SK; Hong TS; Wo JY; Ferrone CR; Tanabe KK; Bardeesy N; Straley KS; Agresta S; Schenkein DP; Ellisen LW; Ryan DP; Zhu AX
    Clin Cancer Res; 2014 Apr; 20(7):1884-90. PubMed ID: 24478380
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
    Stein EM; DiNardo CD; Fathi AT; Mims AS; Pratz KW; Savona MR; Stein AS; Stone RM; Winer ES; Seet CS; Döhner H; Pollyea DA; McCloskey JK; Odenike O; Löwenberg B; Ossenkoppele GJ; Patel PA; Roshal M; Frattini MG; Lersch F; Franovic A; Nabhan S; Fan B; Choe S; Wang H; Wu B; Hua L; Almon C; Cooper M; Kantarjian HM; Tallman MS
    Blood; 2021 Apr; 137(13):1792-1803. PubMed ID: 33024987
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Final phase 1 substudy results of ivosidenib for patients with mutant IDH1 relapsed/refractory myelodysplastic syndrome.
    DiNardo CD; Roboz GJ; Watts JM; Madanat YF; Prince GT; Baratam P; de Botton S; Stein A; Foran JM; Arellano ML; Sallman DA; Hossain M; Marchione DM; Bai X; Patel PA; Kapsalis SM; Garcia-Manero G; Fathi AT
    Blood Adv; 2024 Aug; 8(15):4209-4220. PubMed ID: 38640348
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FDA Approval Summary: Ripretinib for Advanced Gastrointestinal Stromal Tumor.
    Kumar V; Doros L; Thompson M; Mushti SL; Charlab R; Spehalski EI; Zhao H; Thompson MD; Tang S; Pazdur R; Lemery SJ; Theoret MR; Fashoyin-Aje LA
    Clin Cancer Res; 2023 Jun; 29(11):2020-2024. PubMed ID: 36485007
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ivosidenib for IDH1 Mutant Cholangiocarcinoma: A Narrative Review.
    Sumbly V; Landry I; Rizzo V
    Cureus; 2022 Jan; 14(1):e21018. PubMed ID: 35154988
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Effect of FGFR2 Alterations on Overall and Progression-Free Survival in Patients Receiving Systemic Therapy for Intrahepatic Cholangiocarcinoma.
    Abou-Alfa GK; Bibeau K; Schultz N; Yaqubie A; Millang B; Ren H; Féliz L
    Target Oncol; 2022 Sep; 17(5):517-527. PubMed ID: 36114955
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.